164 related articles for article (PubMed ID: 15160345)
1. Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma.
Rizzieri DA; Sand GJ; McGaughey D; Moore JO; DeCastro C; Chao NJ; Vredenburgh JJ; Gasparetto C; Long GD; Anderson E; Foster T; Toaso B; Adams D; Niedzwiecki D; Gockerman JP
Cancer; 2004 Jun; 100(11):2408-14. PubMed ID: 15160345
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
Borghaei H; Millenson M; Schilder R; Alden M; Rogatko A; Wang H; Padavic-Shaller K; Smith MR
Cancer; 2004 Nov; 101(9):2034-41. PubMed ID: 15455357
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
Casasnovas RO; Haioun C; Dumontet C; Gabarre J; Richard B; Lederlin P; Caillot D; Stamatoullas A; Morel P; Quesnel B; Blay JY; Bouabdallah K; Gisselbrecht C
Haematologica; 2000 May; 85(5):502-7. PubMed ID: 10800167
[TBL] [Abstract][Full Text] [Related]
4. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
Musolino A; Perrone MA; Michiara M; Delnevo D; Franciosi V; Di Blasio B; Ceci G; Camisa R; Ardizzoni A; Cocconi G
Cancer; 2005 May; 103(10):2109-17. PubMed ID: 15803492
[TBL] [Abstract][Full Text] [Related]
5. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
6. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study.
Kahl BS; Bailey HH; Smith EP; Turman N; Smith J; Werndli J; Williams EC; Longo WL; Kim KM; McGovern J; Jumonville A
Cancer Invest; 2005; 23(1):13-8. PubMed ID: 15779863
[TBL] [Abstract][Full Text] [Related]
8. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
Aydin S; Dührsen U; Nückel H
Ann Hematol; 2007 Apr; 86(4):271-6. PubMed ID: 17216473
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
10. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
[TBL] [Abstract][Full Text] [Related]
11. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
Bremer K
J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
[TBL] [Abstract][Full Text] [Related]
12. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma.
Ferrari AC; Chachoua A; Singh H; Rosenthal M; Taneja S; Bednar M; Mandeli J; Muggia F
Cancer; 2001 Jun; 91(11):2039-45. PubMed ID: 11391583
[TBL] [Abstract][Full Text] [Related]
13. Hyperfractionated cyclophosphamide with high-doses of arabinosylcytosine and methotrexate (HyperCHiDAM Verona 897).
Todeschini G; Tecchio C; Pasini F; Benedetti F; Cantini M; Crippa C; Draisci M; Pizzolo G
Cancer; 2005 Aug; 104(3):555-60. PubMed ID: 15959910
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG).
Crump M; Baetz T; Couban S; Belch A; Marcellus D; Howson-Jan K; Imrie K; Myers R; Adams G; Ding K; Paul N; Shepherd L; Iglesias J; Meyer R
Cancer; 2004 Oct; 101(8):1835-42. PubMed ID: 15386331
[TBL] [Abstract][Full Text] [Related]
15. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma.
Oki Y; McLaughlin P; Pro B; Hagemeister FB; Bleyer A; Loyer E; Younes A
Cancer; 2005 Aug; 104(4):781-7. PubMed ID: 15973667
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Wiernik PH; Lossos IS; Tuscano JM; Justice G; Vose JM; Cole CE; Lam W; McBride K; Wride K; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Habermann TM
J Clin Oncol; 2008 Oct; 26(30):4952-7. PubMed ID: 18606983
[TBL] [Abstract][Full Text] [Related]
18. Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study.
Rodriguez MA; Pytlik R; Kozak T; Chhanabhai M; Gascoyne R; Lu B; Deitcher SR; Winter JN;
Cancer; 2009 Aug; 115(15):3475-82. PubMed ID: 19536896
[TBL] [Abstract][Full Text] [Related]
19. High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
Buckstein R; Kerbel RS; Shaked Y; Nayar R; Foden C; Turner R; Lee CR; Taylor D; Zhang L; Man S; Baruchel S; Stempak D; Bertolini F; Crump M
Clin Cancer Res; 2006 Sep; 12(17):5190-8. PubMed ID: 16951238
[TBL] [Abstract][Full Text] [Related]
20. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
